Clinicians, big pharma, public health officials, farmers, lawyers, charities, manufacturers and academics all raise their voice in this issue to point towards the increasing threat of antimicrobial resistance. In ten individual “commandments”, they speak about a needed global awareness campaign, improved hygiene, the reduction of antimicrobials in agriculture, humans and animals and the importance of diagnostics. But also the necessity to improve pay and recognition of people working in infectious diseases and better incentives to promote investment for new drugs. Last but not least, the authors call for a Global Innovation Fund for early-stage and non-commercial research and a global coalition for real action – via the G20 and the UN.
Kevin Outterson, executive director of Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) contributes a comprehensive overview of all major AMR development initiatives including JPIAMR, GARDP, Novo Repair Impact Fund and IMI’s ND4BB to the edition. Selected representatives of these initiatives will also be present at the AMR conference.
Read the AMR Special Issue